文献速递创伤与烧伤消化、代谢与肾脏急症

骨折后血栓预防:阿司匹林与低分子肝素比较

Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture.
PubMed 文献 · N Engl J Med · 2023-01-01
一句话结论在四肢骨折手术或骨盆/髋臼骨折患者中,阿司匹林预防死亡不劣于低分子肝素,但深静脉血栓发生率较高。

这项实用、多中心、随机、非劣效性试验纳入12,211例18岁以上四肢骨折(髋至中足或肩至腕)手术治疗或任何骨盆/髋臼骨折患者,随机接受依诺肝素30 mg每日两次或阿司匹林81 mg每日两次住院期间预防,出院后按各院方案继续。主要终点90天全因死亡:阿司匹林组0.78% vs 低分子肝素组0.73%(差异0.05个百分点;96.2%CI -0.27至0.38;非劣效界值0.75个百分点,P<0.001)。深静脉血栓阿司匹林组2.51% vs 低分子肝素组1.71%(差异0.80个百分点;95%CI 0.28至1.31)。肺栓塞(各组1.49%)、出血并发症及其他严重不良事件两组相似。

要点

  • 90天全因死亡:阿司匹林组0.78%(47例) vs 低分子肝素组0.73%(45例),差异0.05个百分点(96.2%CI -0.27至0.38),非劣效界值0.75个百分点,P<0.001。
  • 深静脉血栓:阿司匹林组2.51% vs 低分子肝素组1.71%,差异0.80个百分点(95%CI 0.28至1.31)。
  • 肺栓塞发生率两组均为1.49%,出血并发症及其他严重不良事件两组相似。
  • 住院期间依诺肝素30 mg每日两次或阿司匹林81 mg每日两次,出院后按各院临床方案继续预防,中位出院带药21天。
  • 患者平均年龄44.6±17.8岁,0.7%有静脉血栓栓塞史,2.5%有癌症史,平均住院预防剂量8.8±10.6次。

适用人群与场景

  • 18岁及以上,四肢骨折(髋至中足或肩至腕任何部位)且已接受手术治疗,或任何骨盆或髋臼骨折的患者。

处置流程与药物剂量

  • 住院期间随机接受依诺肝素30 mg每日两次或阿司匹林81 mg每日两次进行血栓预防。
  • 出院后按各医院临床方案继续血栓预防,中位出院带药21天。

研究设计与关键结果

  • 实用、多中心、随机、非劣效性试验,纳入12,211例患者,随机分为阿司匹林组(6101例)和低分子肝素组(6110例)。
  • 主要终点90天全因死亡:阿司匹林组0.78%(47例) vs 低分子肝素组0.73%(45例),差异0.05个百分点(96.2%CI -0.27至0.38;非劣效界值0.75个百分点,P<0.001)。
  • 深静脉血栓:阿司匹林组2.51% vs 低分子肝素组1.71%,差异0.80个百分点(95%CI 0.28至1.31)。
  • 肺栓塞发生率两组均为1.49%;出血并发症及其他严重不良事件两组相似。
  • 患者平均年龄44.6±17.8岁,0.7%有静脉血栓栓塞史,2.5%有癌症史;平均住院预防剂量8.8±10.6次,出院带药中位21天。

证据类型、等级与局限

  • 证据类型:实用、多中心、随机、非劣效性试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在四肢骨折手术治疗或任何骨盆/髋臼骨折患者中,阿司匹林血栓预防在预防死亡方面不劣于低分子肝素,且深静脉血栓、肺栓塞发生率及90天死亡率均较低。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Clinical guidelines recommend low-molecular-weight heparin for thromboprophylaxis in patients with fractures, but trials of its effectiveness as compared with aspirin are lacking.

METHODS: In this pragmatic, multicenter, randomized, noninferiority trial, we enrolled patients 18 years of age or older who had a fracture of an extremity (anywhere from hip to midfoot or shoulder to wrist) that had been treated operatively or who had any pelvic or acetabular fracture. Patients were randomly assigned to receive low-molecular-weight heparin (enoxaparin) at a dose of 30 mg twice daily or aspirin at a dose of 81 mg twice daily while they were in the hospital. After hospital discharge, the patients continued to receive thromboprophylaxis according to the clinical protocols of each hospital. The primary outcome was death from any cause at 90 days. Secondary outcomes were nonfatal pulmonary embolism, deep-vein thrombosis, and bleeding complications.

RESULTS: A total of 12,211 patients were randomly assigned to receive aspirin (6101 patients) or low-molecular-weight heparin (6110 patients). Patients had a mean (±SD) age of 44.6±17.8 years, 0.7% had a history of venous thromboembolism, and 2.5% had a history of cancer. Patients received a mean of 8.8±10.6 in-hospital thromboprophylaxis doses and were prescribed a median 21-day supply of thromboprophylaxis at discharge. Death occurred in 47 patients (0.78%) in the aspirin group and in 45 patients (0.73%) in the low-molecular-weight-heparin group (difference, 0.05 percentage points; 96.2% confidence interval, -0.27 to 0.38; P<0.001 for a noninferiority margin of 0.75 percentage points). Deep-vein thrombosis occurred in 2.51% of patients in the aspirin group and 1.71% in the low-molecular-weight-heparin group (difference, 0.80 percentage points; 95% CI, 0.28 to 1.31). The incidence of pulmonary embolism (1.49% in each group), bleeding complications, and other serious adverse events were similar in the two groups.

CONCLUSIONS: In patients with extremity fractures that had been treated operatively or with any pelvic or acetabular fracture, thromboprophylaxis with aspirin was noninferior to low-molecular-weight heparin in preventing death and was associated with low incidences of deep-vein thrombosis and pulmonary embolism and low 90-day mortality. (Funded by the Patient-Centered Outcomes Research Institute; PREVENT CLOT ClinicalTrials.gov number, NCT02984384.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. O'Toole RV, Stein DM, O'Hara NN, et al. Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture. N Engl J Med. 2023. PMID: 36652352. doi:10.1056/NEJMoa2205973

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。